This is a preview and has not been published.

Association between anti-inflammatory effect of infliximab and small fiber neuropathy symptoms in patients with sarcoidosis

Effects of anti-TNF-alpha on SFN and sarcoidosis

Authors

  • Lisette Raasing
  • Oscar J.M. Vogels ILD Center of Excellence, Department of Neurology, St Antonius Hospital (3435 CM, Nieuwegein, The Netherlands)
  • Marcel Veltkamp ILD Center of Excellence, Department of Pulmonology, St Antonius Hospital (3435 CM, Nieuwegein, The Netherlands)
  • Jan C. Grutters Division of Heart and Lungs, University Medical Center Utrecht (3584 CX, Utrecht, The Netherlands)

DOI:

https://doi.org/10.36141/svdld.v39i4.12031

Keywords:

small fiber neuropathy, sarcoidosis, infliximab, treatment, SFNSL

Abstract

Introduction Small fiber neuropathy (SFN) may present as complication in sarcoidosis.1 SFN can potentially result into a large range of symptoms with a high impact on quality of life.2 Although treatment of the underlying disease of SFN is paramount, little research has been performed to investigate SFN improvement as consequence of sarcoidosis treatment. This retrospective study investigates whether there is an association between the anti-inflammatory effects of infliximab and SFN-symptoms 

Methods The Small Fiber Neuropathy Screening List (SFNSL) was used to identify changes in SFN symptoms during Infliximab treatment. Maximal standardized uptake value (SUVmax) from Fluordeoxyglucose Positron Emission Tomography (FDG-PET) was used as a measure for inflammatory activity. To investigate the effects of Infliximab on inflammatory activity, a subdivision was made defined as improved, stable and worsened SFNSL-score.

            Results 45 sarcoidosis patients were eligible for analysis. SFNSL-score showed a mean decrease of -3 points (p = 0.207). SUVmax did improve with a mean of 3.44 (p=<0.001). In the subgroups of ameliorated, stable and worse SFN-related symptoms, only in the latter subgroup the improvement of FDG uptake was not clinically relevant.

            Discussion In patients with active inflammatory sarcoidosis defined by FDG-PET, Infliximab treatment showed an improvement of the SFNSL-score in 51% of patients. In these patients a significant decrease of sarcoidosis inflammation measured by FDG-PET was also found. In most of the patients without clinically relevant improvement of SUVmax, the SFNSL-score worsened. These data could open a discussion about whether persistent inflammation in sarcoidosis can be detrimental to symptoms of SFN.

Downloads

Download data is not yet available.

##submission.authorBiographies##

##submission.authorWithAffiliation##

Neurologist

##submission.authorWithAffiliation##

pulmonologist

##submission.authorWithAffiliation##

professor and pulmonologist

##submission.citations##

Tavee J, Culver D. Sarcoidosis and small-fiber neuropathy. Current Pain and Headache Reports 2011; 15:201–206.

Bakkers M, Faber CG, Hoeijmakers JGJ, Lauria G, Merkies ISJ. Small Fibers, Large Impact: Quality of Life in Small-Fiber Neuropathy. Vol 49., 2014.

Grunewald J, Grutters JC, Arkema E V., Saketkoo LA, Moller DR, Müller-Quernheim J. Sarcoidosis. Nature Reviews Disease Primers 2019; 5.

Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet P-Y, Müller-Quernheim J. Sarcoidosis. Vol 103., 2014.

Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014; 11:1304–1323. P

Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, Du Bois R, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. American Journal of Respiratory and Critical Care Medicine 2006; 174:795–802.

Voortman M, Hendriks CMR, Elfferich MDP, Bonella F, Møller J, De Vries J, et al. The Burden of Sarcoidosis Symptoms from a Patient Perspective. Lung 2019; 197:155–161.

Voortman M, Fritz D, Vogels OJM, Eftimov F, Van De Beek D, Brouwer MC, et al. Small fiber neuropathy: A disabling and underrecognized syndrome. Current Opinion in Pulmonary Medicine 2017; 23:447–457.

Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA. Health-related quality of life of persons with sarcoidosis. Chest 2004; 125:997–1004. Published online: 2004.

De Vries J, Wirnsberger RM. Fatigue, quality of life and health status in sarcoidosis. Sarcoidosis 2010:92–104.

Parambil JG, Tavee JO, Zhou L, Pearson KS, Culver DA. Efficacy of intravenous immunoglobulin for small fiber neuropathy associated with sarcoidosis. Respiratory Medicine 2011; 105:101–105.

Hoitsma E, Faber C, Santen-Hoeufft M van, Vries J de, Reulen J, Drenth M. Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab. Sarcoidosis Vasculitis and Diffuse Lung Diseases 2006; 23:73–77.

Van Velzen M, Heij L, Niesters M, Cerami A, Dunne A, Dahan A, et al. Ara 290 for treatment of small fiber neuropathy in sarcoidosis. Expert Opinion on Investigational Drugs 2014; 23:541–550.

Costabel U, Hunninghake GW, Statement S. EDITORIAL ATS / ERS / WASOG statement on sarcoidosis. Eur Respir J 1999; 14:735–737.

Hoitsma E, De Vries J, Drent M. The small fiber neuropathy screening list: Construction and cross-validation in sarcoidosis. Respiratory Medicine 2011; 105:95–100.

Voortman M, Beekman E, Drent M, Hoitsma E, De Vries J. Determination of the smallest detectable change (SDC) and the minimal important difference (MID) for the small fiber neuropathy screening list (SFNSL) in sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases 2018; 35:333–341.

Pinker K, Riedl C, Weber WA. Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments. European Journal of Nuclear Medicine and Molecular Imaging 2017; 44:55–66. Published online: 2017.

Vorselaars ADM, Crommelin HA, Deneer VHM, Meek B, Claessen AME, Keijsers RGM, et al. Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis. European Respiratory Journal 2015; 46:175–185.

Keijsers RG, Verzijlbergen FJ, Oyen WJ, Van Den Bosch JM, Ruven HJ, Van Velzen-Blad H, et al. 18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis. European Journal of Nuclear Medicine and Molecular Imaging 2009; 36:1131–1137.

Wijnen PA, Cremers JP, Nelemans PJ, Erckens RJ, Hoitsma E, Jansen TL, et al. Association of the TNF-α G-308A polymorphism with TNF-inhibitor response in sarcoidosis. European Respiratory Journal 2014; 43:1730–1739.

Tavee JO, Karwa K, Ahmed Z, Thompson N, Parambil J, Culver DA. Sarcoidosis-Associated Small Fiber Neuropathy in a Large Cohort: Clinical Aspects and Response to IVIG and Anti-TNF Alpha Treatment. Vol 126. Elsevier Ltd, 2017.

Vis R, van de Garde EMW, Meek B, Korenromp IHE, Grutters JC. Randomised, placebo-controlled trial of dexamethasone for quality of life in pulmonary sarcoidosis. Respiratory Medicine 2020; 165.

Issue

Section

Original Articles: Clinical Research

Most read articles by the same author(s)